Bi-specific CAR-iNKT cell immunotherapy for high-risk KMT2A-rearranged leukemia outperforms CAR-T in an NKG2D-dependent manner and eradicates leptomeningeal disease
Ren, H.; Elliott, N.; Lye, B.; Shohan, M.; Cross, J.; Field, L.; Ponnusamy, K.; Rice, S.; Jackson, T.; Leontari, I.; Ouazzani, N.; Thomas, R.; Inglott, S.; Bartram, J.; Smith, O.; Bond, J.; Roberts, I. A.; Halsey, C.; Bashford-Rogers, R. J. M.; Milne, T.; Roy, A.; Karadimitris, A.
Show abstract
Current therapies, including autologous CAR-T immunotherapy, fail to cure half of infants with KMT2A-rearranged acute lymphoblastic leukemia (KMT2Ar-ALL). Here we deploy allogeneic iNKT cells, innately more powerful effectors than T cells, and equip them with CD19- and/or CD133-targeting CARs. Compared to mono-specific counterparts and bi-specific CAR-T, CD19-CD133 bi-specific CAR-iNKT have more potent anti-leukemia activity, they effectively target CAR antigen-low leukemia, eradicate medullary and leptomeningeal leukemia and induce sustained remissions without discernible hematologic toxicity. Mechanistically, dynamic CAR- and CAR antigen-dependent upregulation of the activating innate receptor NKG2D and its engagement by corresponding ligands on KMT2Ar-ALL cells lead to more potent anti-leukemia effect of CAR-iNKT over CAR-T cells, including against CAR antigen-negative leukemia. Thus, by engaging with two different types of leukemia-associated targets, CAR-iNKT provide a powerful platform for the treatment of KMT2Ar-ALL. This approach can be readily adapted for other high-risk malignancies, including those with otherwise difficult to target leptomeningeal involvement.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML 96%
- Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network 96%
- Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties 96%
Similar papers in this journal
- Role of Stem-Like Cells in Chemotherapy Resistance and Relapse in pediatric T Cell Acute Lymphoblastic Leukemia 97%
- Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth 97%
- Endowing Universal CAR T-cell with Immune-Evasive Properties using TALEN-Gene Editing. 96%
Similar papers in this journal
- Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia 98%
- Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition 97%
- A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy 95%
Similar papers in this journal
- Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities 97%
- Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes 95%
- Hematopoietic fitness of JAK2 V617F Myeloproliferative Neoplasms is linked to clinical outcome 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.